Bordoni A, Lopez-Jimenez J A, Spanò C, Biagi P, Horrobin D F, Hrelia S
Department of Biochemistry G. Moruzzi, University of Bologna, Italy.
Mol Cell Biochem. 1996;157(1-2):217-22. doi: 10.1007/978-1-4613-1275-8_27.
The metabolites of linoleic (LA) and alpha-linolenic (ALA) acids are involved in coronary heart disease. Both n-6 and n-3 essential fatty acids (EFAs) are likely to be important in prevention of atherosclerosis since the common risk factors are associated with their reduced 6-desaturation. We previously demonstrated the ability of heart tissue to desaturate LA. In this study we examined the ability of cultured cardiomyocytes to metabolize both LA and ALA in vivo, in the absence and in the presence of gamma linolenic acid (GLA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) alone or combined together. In control conditions, about 25% or LA and about 90% of ALA were converted in PUFAs. GLA supplementation had no influence on LA conversion to more unsaturated fatty acids, while the addition of n-3 fatty acids, alone or combined together, significantly decreased the formation of interconversion products from LA. Using the combination of n-6 and n-3 PUFAs, GLA seemed to counterbalance partially the inhibitory effect of EPA and DHA on LA desaturation/elongation. The conversion of ALA to more unsaturated metabolites was greatly affected by GLA supplementation. Each supplemented fatty acid was incorporated to a significant extent into cardiomyocyte lipids, as revealed by gas chromatographic analysis. The n-6/n-3 fatty acid ratio was greatly influenced by the different supplementations; the ratio in GLA+EPA+DHA supplemented cardiomyocytes was the most similar to that recorded in control cardiomyocytes. Since important risk factors for coronary disease may be associated with reduced 6-desaturation of the parent EFAs, administration of n-6 or n-3 EFA metabolites alone could cause undesirable effects. Since they appear to have different and synergistic roles, only combined treatment with both n-6 and n-3 metabolites is likely to achieve optimum results.
亚油酸(LA)和α-亚麻酸(ALA)的代谢产物与冠心病有关。n-6和n-3必需脂肪酸(EFA)在预防动脉粥样硬化中可能都很重要,因为常见的风险因素与它们降低的6-去饱和作用有关。我们之前证明了心脏组织使LA去饱和的能力。在本研究中,我们检测了培养的心肌细胞在体内代谢LA和ALA的能力,分别在不存在和存在γ-亚麻酸(GLA)、二十碳五烯酸(EPA)、二十二碳六烯酸(DHA)单独或联合使用的情况下。在对照条件下,约25%的LA和约90%的ALA被转化为多不饱和脂肪酸(PUFA)。补充GLA对LA转化为更多不饱和脂肪酸没有影响,而单独或联合添加n-3脂肪酸显著降低了LA相互转化产物的形成。使用n-6和n-3 PUFA的组合时,GLA似乎部分抵消了EPA和DHA对LA去饱和/延长的抑制作用。补充GLA对ALA向更多不饱和代谢产物的转化有很大影响。气相色谱分析显示,每种补充的脂肪酸都有很大程度地掺入心肌细胞脂质中。不同的补充剂对n-6/n-3脂肪酸比例有很大影响;补充GLA+EPA+DHA的心肌细胞中的比例与对照心肌细胞中记录的比例最相似。由于冠心病的重要风险因素可能与母体EFA的6-去饱和作用降低有关,单独给予n-6或n-3 EFA代谢产物可能会产生不良影响。由于它们似乎具有不同的协同作用,只有同时使用n-6和n-3代谢产物进行联合治疗才可能取得最佳效果。